Aiming at the obvious high uptake of the PSMA ligand in the left lobe of the prostate, we targeted the basal part of the left lobe, successfully detected prostate tumor tissue, and laid a pathological foundation for subsequent treatment. Here, FOLH1 is linked to prostate neoplasm.